Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 9:15:1329743.
doi: 10.3389/fphar.2024.1329743. eCollection 2024.

A Chinese classical prescription Maimendong decoction in treatment of pulmonary fibrosis: an overview

Qiurong Lao  1 , Xianbin Wang  1 , Guangqing Zhu  1 , Haochen Yuan  1 , Ting Ma  2 , Ning Wang  3
Affiliations
Review

A Chinese classical prescription Maimendong decoction in treatment of pulmonary fibrosis: an overview

Qiurong Lao et al. Front Pharmacol. .

Abstract

Pulmonary fibrosis (PF) is a chronic and progressive disease characterized by fibrosis and interstitial pneumonia. It has similar clinical symptoms to "Fei Bi" and "Fei Wei" as described in the traditional Chinese medicine (TCM) classic Jingui Yaolue written by Zhang Zhongjing in the Han Dynasty. This study explored the potential of Maimendong Decoction (MMDD). MMDD consists of Ophiopogon japonicus (L.f) (ophiopogonis), Pinellia ternata (Thunb.) Breit. (pinellia), Panax ginseng C. A. Mey. (ginseng), Glycyrrhiza uralensis Fisch. (glycyrrhiza), Zizi phus jujuba Mill. (jujuba), and Oryza sativa L. (oryza sativa), with the function of nourishing the lung and stomach, and reducing the effect of reverse qi. It has been used clinically for over two thousand years to treat conditions like "Fei Bi" and "Fei Wei". Previous research suggests that MMDD and its individual herbal extracts have anti-fibrotic effects. The main focus of MMDD in treating PF is to reduce inflammatory cytokines, inhibit pro-fibrotic factors and oxidative stress, promote differentiation and homing of bone marrow mesenchymal stem cells, and enhance cell autophagy activity. This review summarized the clinical applications, mechanisms, and pharmacological effects of MMDD in treating PF based on existing clinical applications and experimental research. It also discussed current issues and prospects, aiming to provide a reference for further research on the mechanism of PF, drug development, and clinical trials.

Keywords: Maimendong decoction; classical prescription of traditional Chinese medicine; mechanism; pharmacological effects; pulmonary fibrosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Composition and dosage of Maimendong Dection (Maimendong Dection composed of ophiopogonis, pinellia, ginseng, glycyrrhiza, jujuba and oryza sativa).
FIGURE 2
FIGURE 2
Mechanism of Maimendong Dection in the treatment of pulmonary fibrosis (the mechanism of MMDD in the treatment of Pulmonary fibrosis is mainly focused on reducing the level of inflammatory cytokines, inhibiting the expression of pro-fibrotic factors, inhibiting oxidative stress injury, promoting the differentiation and homing of bone marrow mesenchymal stem cells, and enhancing cell autophagy activity).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Baby J., Devan A. R., Kumar A. R., Gorantla J. N., Nair B., Aishwarya T. S., et al. (2021). Cogent role of flavonoids as key orchestrators of chemoprevention of hepatocellular carcinoma: a review. J. Food Biochem. 45 (7), e13761. 10.1111/jfbc.13761 - DOI - PubMed
    1. Bai W. M., Wang B., Liao C. Y. (2019). Effect of Maimendong decoction on carbon monoxide diffusion capacity, serum HA level and TCM syndrome score in patients with idiopathic pulmonary fibrosis. J. Sichuan Tradit. Chin. 37 (8), 92–95.
    1. Bhavana K., Puneet K., Soumya S. (2021). Pulmonary fibrosis in COVID-19 recovered patients: problem and potential management. Indian J. Crit. care Med. peer-reviewed 25 (2), 242–244. 10.5005/jp-journals-10071-23733 - DOI - PMC - PubMed
    1. Cai F. L., Wang M. F., Cheng X. Q., Yuan L. Y., He J. J., W H. W., et al. (2022). Effect and mechanism of isoglycyrrhizin on in vitro pulmonary fibrosis model. Her. Med. 41 (02), 167–174. 10.3870/j.issn.1004-0781.2022.02.005 - DOI
    1. Cao Z. Y., Liu Y. Z., Li J. M., Ruan Y. M., Yan W. J., Zhong S. Y., et al. (2020). Glycyrrhizic acid as an adjunctive treatment for depression through anti-inflammation: a randomized placebo-controlled clinical trial. J. Affect Disord. 265, 247–254. 10.1016/j.jad.2020.01.048 - DOI - PubMed

LinkOut - more resources